Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 11/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045532 | 0.96 | EGFR (0.47) | EGFRPDGFRBHDAC3HDAC4HDAC1 | |
| SCHEMBL4044224 | 0.96 | FBP1 (0.42) | GRM4EGFRPDGFRBHDAC3HDAC4 | |
| SCHEMBL4042307 | 0.90 | PDGFRB (0.43) | GRM4EGFRPDGFRBHDAC3HDAC4 | |
| SCHEMBL4041172 | 0.88 | FBP1 (0.47) | GRM4EGFRPDGFRBERBB2 | |
| SCHEMBL4040847 | 0.88 | PDGFRB (0.47) | EGFRPDGFRBERBB2 | |
| SCHEMBL4043071 | 0.87 | PDGFRB (0.48) | EGFRPDGFRBCHEK1KDR | |
| SCHEMBL13145432 | 0.86 | CHEK1 (0.36) | GRM4PDGFRBCHEK1KDR | |
| SCHEMBL4044252 | 0.85 | EGFR (0.54) | EGFRPDGFRBHDAC3HDAC4HDAC1 | |
| SCHEMBL3087012 | 0.85 | PDGFRB (0.48) | PDGFRBCHEK1KDR | |
| SCHEMBL4044415 | 0.84 | PDGFRB (0.55) | GRM4EGFRPDGFRBERBB2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | claimed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | claimed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | claimed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | claimed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | claimed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1319659-B1 | TRIAZINONES AND MEDICINAL USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1319659-A1 | PYRIDAZINONES AND TRIAZINONES AND MEDICINAL USE THEREOF | Eisai Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | GRM4 3532/4885EGFR 26/4885PDGFRB 2/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | GRM4 3491/4885EGFR 24/4885PDGFRB 2/4885 |
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | GRM4 96/4885EGFR 876/4885PDGFRB 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.